EP 4065120 A1 20221005 - N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS
Title (en)
N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE CFTR MODULATORS FOR THE TREATMENT OF CYSTIC FIBROSIS
Title (de)
N2-ARYLMETHYL-4-HALOGENALKYL-PYRIDAZIN-3-ONE CFTR-MODULATOREN FÜR DIE BEHANDLUNG VON ZYSTISCHER FIBROSE
Title (fr)
MODULATEURS DE CFTR DE TYPE N2-ARYLMETHYL-4-HALOALKYL-PYRIDAZIN-3-ONE POUR LE TRAITEMENT DE LA MUCOVISCIDOSE
Publication
Application
Priority
- FR 1913404 A 20191128
- FR 2020052228 W 20201130
Abstract (en)
[origin: WO2021105641A1] The invention relates to compounds of formula I (I) or pharmaceutically acceptable solvates thereof, as well as their use in the treatment and/or prevention of diseases or conditions associated with a dysfunction of CFTR channel activity, particularly cystic fibrosis.
IPC 8 full level
A61K 31/501 (2006.01); A61K 45/06 (2006.01); A61P 11/00 (2006.01); A61P 11/06 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01)
CPC (source: EP US)
A61K 31/501 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 11/00 (2017.12 - EP); A61P 11/06 (2017.12 - EP); C07D 237/14 (2013.01 - EP US); C07D 401/04 (2013.01 - EP US); C07D 409/06 (2013.01 - EP US)
Citation (search report)
See references of WO 2021105641A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2021105641 A1 20210603; CA 3163176 A1 20210603; CN 114945368 A 20220826; EP 4065120 A1 20221005; FR 3103701 A1 20210604; FR 3103701 B1 20211126; US 2023013304 A1 20230119
DOCDB simple family (application)
FR 2020052228 W 20201130; CA 3163176 A 20201130; CN 202080092401 A 20201130; EP 20828531 A 20201130; FR 1913404 A 20191128; US 202017780148 A 20201130